Great Lakes Advisors LLC Takes $1.70 Million Position in Hims & Hers Health, Inc. $HIMS

Great Lakes Advisors LLC bought a new position in Hims & Hers Health, Inc. (NYSE:HIMS) during the third quarter, according to the company in its most recent filing with the SEC. The firm bought 30,018 shares of the company’s stock, valued at approximately $1,703,000.

Several other hedge funds have also added to or reduced their stakes in the business. Virtus Advisers LLC bought a new position in shares of Hims & Hers Health during the second quarter valued at about $26,000. Quent Capital LLC purchased a new stake in Hims & Hers Health during the 3rd quarter valued at about $28,000. Quaker Wealth Management LLC purchased a new stake in Hims & Hers Health during the 2nd quarter valued at about $29,000. Geneos Wealth Management Inc. bought a new position in Hims & Hers Health during the 1st quarter worth approximately $30,000. Finally, Bessemer Group Inc. increased its stake in Hims & Hers Health by 105.8% in the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after purchasing an additional 312 shares during the period. 63.52% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

HIMS has been the subject of a number of analyst reports. Bank of America increased their price objective on Hims & Hers Health from $28.00 to $32.00 and gave the company an “underperform” rating in a research note on Tuesday, November 4th. KeyCorp started coverage on shares of Hims & Hers Health in a research report on Tuesday, October 21st. They set a “sector weight” rating for the company. Weiss Ratings reissued a “hold (c)” rating on shares of Hims & Hers Health in a report on Monday, December 29th. BTIG Research restated a “buy” rating and issued a $85.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, November 4th. Finally, Barclays assumed coverage on shares of Hims & Hers Health in a report on Monday, December 8th. They set an “overweight” rating and a $48.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have assigned a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat, Hims & Hers Health presently has an average rating of “Hold” and an average price target of $44.54.

Insider Activity

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 23,187 shares of the firm’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $36.81, for a total transaction of $853,513.47. Following the completion of the sale, the chief financial officer directly owned 70,232 shares in the company, valued at approximately $2,585,239.92. This trade represents a 24.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Deborah M. Autor sold 7,054 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $258,952.34. Following the completion of the transaction, the insider owned 6,175 shares in the company, valued at approximately $226,684.25. This represents a 53.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 131,974 shares of company stock valued at $4,763,800. 13.71% of the stock is currently owned by insiders.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $27.15 on Friday. The company has a 50 day simple moving average of $34.34 and a two-hundred day simple moving average of $44.31. Hims & Hers Health, Inc. has a fifty-two week low of $23.97 and a fifty-two week high of $72.98. The company has a market capitalization of $6.18 billion, a price-to-earnings ratio of 50.28, a P/E/G ratio of 4.92 and a beta of 2.37. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.03). The company had revenue of $598.98 million during the quarter, compared to analysts’ expectations of $578.99 million. Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The business’s quarterly revenue was up 49.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.32 EPS. Analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health announced that its Board of Directors has approved a stock repurchase plan on Monday, November 17th that allows the company to buyback $250.00 million in outstanding shares. This buyback authorization allows the company to repurchase up to 3% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its stock is undervalued.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.